Achievement of the National Psoriasis Foundation Treatment Targets With Ixekizumab: Pooled Analyses From Four Clinical Studies.
The National Psoriasis Foundation (NPF) published treatment targets for US patients with plaque psoriasis. However, data are lacking on how well existing therapies help achieve these goals. We examined the ability of an IL-17 inhibitor, ixekizumab, in achieving these treatment targets. Post-hoc analysis was performed on data from four Phase III clinical trials assessing IXE for plaque psoriasis: pooled data from the UNCOVER-1, -2, and -3 trials, and data from the IXORA-S trial. Treatment response was evaluated using NPF-defined acceptable response (AR: BSA ≤3% or BSA improvement ≥75% at 12 weeks of treatment) and target response (TR: BSA ≤1% at 12 weeks and every 6 months thereafter). In UNCOVER studies (n=2701), AR and TR rates at Week 12 were 73.9% and 51.8% with IXE Q2W, 35.7% and 14.9% with etanercept and 3.0% and 0.6% with placebo, respectively. In IXORA-S (n=302), AR and TR rates at Week 12 were significantly higher with IXE Q2W versus ustekinumab (AR: 68.4% vs 38.6%, p<.0001; TR: 50.7% vs 24.1%, p<.0001). Data were from controlled studies and may not reflect real-world practice. The majority of IXE-treated subjects in four phase III clinical trials achieved NPF, patient-centered treatment targets.